C

Celldex Therapeutics

D
CLDX
USD
-1.17
(-4.233%)
Market Closed
17,091.00
Volume
-2.5
EPS
-
Div Yield
-9.625455
P/E
1,754,632,666.12
Market Cap
Today
-4.2330%
1 Week
1.808%
1 Month
-12.870%
6 Months
-37.349%
12 Months
-8.756%
Year To Date
-33.207%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRK
MRK
0.46
(0.4567%)
USD
NVS
NVS
0.23
(0.2153%)
USD
PFE
PFE
0.105
(0.3839%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
AZN
AZN
0.835
(1.308%)
USD
GILD
GILD
6.36
(6.9463%)
USD
AMGN
AMGN
0.28
(0.087%)
USD

Title:
Celldex Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Do you need help or have a question?
Contact Us